Global Amyloidosis Market Spotlight Report 2021: GlaxoSmithKline, Bristol Myers Squibb, and Pfizer have the Highest Number of Completed Clinical Trials with 5 Each
The publisher estimates that in 2017, there were approximately 90,500 incident cases of amyloidosis worldwide, with the highest proportion being the primary (amyloid light-chain; AL) amyloidosis type.
- The publisher estimates that in 2017, there were approximately 90,500 incident cases of amyloidosis worldwide, with the highest proportion being the primary (amyloid light-chain; AL) amyloidosis type.
- Among multiple myeloma cases, the publisher estimates there were approximately 19,300 incident cases of AL amyloidosis worldwide in 2017.
- GlaxoSmithKline, Bristol Myers Squibb, and Pfizer have the highest number of completed clinical trials for amyloidosis, with five trials each.
- GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for amyloidosis.